Modality
ERT
MOA
STINGag
Target
GPRC5D
Pathway
PI3K/AKT
ET
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
Feb 2017
→ Feb 2025
Phase 1Current
NCT03710916
733 pts·ET
2017-02→2025-02·Not yet recruiting
733 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-051.1y agoPh2 Data· ET
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P1/2
Not yet…
Catalysts
Ph2 Data
2025-02-05 · 1.1y ago
ET
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03710916 | Phase 1/2 | ET | Not yet recr... | 733 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |